KO · Forward model · Bull case
The Bull case, 20 quarters out
Model as of
Each segment is projected from its own operating driver, rolled up into consolidated cash flow, and discounted back to a fair value per share. The assumptions below are editable — change them and every number on this page moves with them.
Six verticals on third-party (external) segment revenue. That choice is deliberate: third-party segment revenue sums to consolidated net operating revenues exactly, whereas total segment revenue would need a -$252M eliminations plug. Segment EBITDA margins are therefore struck on third-party revenue so that revenue times margin returns the right EBITDA dollars, and the check holds at the basis quarter - segment EBITDA of $5,178M less the $240M Corporate EBITDA drag is $4,938M, which is reported operating income of $4,672M plus $266M of depreciation and amortisation. History runs ten quarters, 2024 Q1 to 2026 Q2. Eight of those are the two complete calendar-year windows the seasonal factors are fitted on; the 2024 Q4 and 2025 Q4 points in every vertical are derived as full year less nine months and are flagged estimated. Twelve quarters do not exist and never will: Global Ventures was sunset on 1 January 2025 and only 2024 was recast, so the 2023 quarters survive only on the superseded six-segment basis. Two disclosed facts drive the near path and both are modelled explicitly. Coca-Cola's quarters end on a Friday while its year ends on 31 December, so 2026 Q1 carried six more days than 2025 Q1 and 2026 Q4 will carry six fewer than 2025 Q4; every seasonal factor here was fitted on revenue per day for that reason, which also means a fixed four-factor vector cannot track a day count that rotates year to year and about 1.5% of unmodelled quarterly error remains. And the African bottling operations, under definitive agreement to Coca-Cola HBC with closing expected by the end of 2026, are carried as a -74% level step on Bottling Investments dated to the second projected quarter, removing about $1,127M a quarter. Coca-Cola does not disclose that business's standalone revenue; that figure is the average of two independent derivations bounding it between $1.0bn and $1.4bn, it is assumed, and the bear and bull cases sit at the two ends of that range. What is deliberately absent: the IRS litigation, whose potential impact the company puts at $14.0bn with $6.0bn already on deposit and a $529M recorded estimate, is a contingency rather than an operating driver and is not modelled as a margin or growth effect anywhere in this spec. Free cash flow here is EBITDA less capital expenditure less tax on that difference, the engine's uniform definition; it carries no interest expense and no working capital, so it is not comparable with the company's approximately $12.4bn free cash flow guidance and should not be read against it. One tension is worth stating rather than tuning away. Every driver here is the segment's own 2024 Q2 to 2026 Q2 compound quarterly rate, not a guided quarter, so the base path puts 2026 Q3 at $13.39bn, up 7.5% year over year - ahead of what the company's own third-quarter considerations (about a point of currency tailwind against about a point of acquisitions-and-divestitures headwind, on top of organic growth) would imply. The two-year rate was kept because one guided quarter is a worse estimator of a five-year path than eight quarters of segment history; the gap is real and it is the first thing the 2026 Q3 print will test.
Shares this page's scenario. Driver and horizon edits stay in your browser — the recipient sees the published model.
Latest: $15.66B (2031Q2E)
| Period | Value |
|---|---|
| 2024Q1 | $11.30B |
| 2024Q2 | $12.36B |
| 2024Q3 | $11.85B |
| 2024Q4 | $11.54B |
| 2025Q1 | $11.13B |
| 2025Q2 | $12.54B |
| 2025Q3 | $12.46B |
| 2025Q4 | $11.82B |
| 2026Q1 | $12.47B |
| 2026Q2 | $13.38B |
| 2026Q3E | $13.42B |
| 2026Q4E | $11.34B |
| 2027Q1E | $11.77B |
| 2027Q2E | $13.05B |
| 2027Q3E | $13.08B |
| 2027Q4E | $11.93B |
| 2028Q1E | $12.37B |
| 2028Q2E | $13.70B |
| 2028Q3E | $13.72B |
| 2028Q4E | $12.51B |
| 2029Q1E | $12.95B |
| 2029Q2E | $14.34B |
| 2029Q3E | $14.36B |
| 2029Q4E | $13.09B |
| 2030Q1E | $13.54B |
| 2030Q2E | $14.99B |
| 2030Q3E | $15.02B |
| 2030Q4E | $13.68B |
| 2031Q1E | $14.15B |
| 2031Q2E | $15.66B |
Where each case comes from
Bear case — primary sources
The primary sources this case is built from — filings, calls and posts. Where they are claims by an interested party rather than disclosures, every number in the Bear column is what happens if they are taken at face value.
Q2 2026 release and guidance
- Jul 28, 2026 First quarter 2026 financial results were impacted by six additional days as compared to first quarter 2025, and fourth quarter 2026 financial results will be impacted by six fewer days as compared to fourth quarter 2025.
- Jul 28, 2026 Approx. 1% currency tailwind [and] 2% to 3% headwind from acquisitions and divestitures.
Sell-side estimates
Bull case — primary sources
The primary sources this case is built from — filings, calls and posts. Where they are claims by an interested party rather than disclosures, every number in the Bull column is what happens if they are taken at face value.
The three 2026 guidance updates
- Feb 10, 2026 comparable EPS (non-GAAP) growth of 7% to 8% versus $3.00 in 2025 [and] organic revenue (non-GAAP) growth of 4% to 5%.
- Jul 28, 2026 Comparable EPS (non-GAAP) 9% to 10% growth, which includes: Approx. 3% currency tailwind [and] Approx. 1% headwind from acquisitions and divestitures. Prior: 8% to 9% growth.
- Jul 28, 2026 comparable operating margin (non-GAAP) was 35.6% versus 34.7% in the prior year.
Braun case — primary sources
The primary sources this case is built from — filings, calls and posts. Where they are claims by an interested party rather than disclosures, every number in the Braun column is what happens if they are taken at face value.
Q2 2026 volume and campaign disclosure
- Jul 28, 2026 Global Unit Case Volume Grew 5%... led by India, China, the United States and Brazil.
- Jul 28, 2026 organic revenues (non-GAAP) grew 6%, driven by a 4% increase in concentrate sales and 2% growth in price/mix.
- Jul 28, 2026 Coca-Cola Reports Second Quarter 2026 Results and Raises Full Year Guidance
From cash flow to fair value
The published model, discounted at 8.0% a year with an exit multiple of 24.0x on EBITDA. The sliders above do not change this walk.
| Present value of free cash flow, 20 quarters | $65.46B |
| Terminal-year revenue | $58.52B |
| Terminal-year EBITDA | $23.61B |
| Exit multiple, on EBITDA | 24.0x |
| Terminal value | $566.65B |
| Discounted at 8.0% a year, terminal value becomes | $385.65B |
| Share of enterprise value from the terminal | 85% |
| Enterprise value | $451.12B |
| Net cash | −$27.17B |
| Equity value | $423.95B |
| Shares | 4.30B |
| Fair value per share | $98.53 |
| Against the deployed price of $87.83, as of | +12% |
At $90.08 and $27.17bn of net debt the enterprise is worth $414.7bn, which is 24.2 times trailing EBITDA once the $1,274M African bottling charge is added back, and 26.1 times without that adjustment. The 21.0x exit is three turns below the adjusted figure: a mature staple should not be assumed to hold a peak multiple five years out. PepsiCo's 12.5x is not the target - that is a business-model gap between a concentrate licensor and a consolidated snacks and bottling group, not a mispricing - and the answer here is more sensitive to this multiple than to any operating assumption in the spec.
Read the other way round: at $87.83 the market is paying 21.1x terminal-year EBITDA, holding every other assumption on this page fixed. That is the number to argue about.
Capex outside the verticals
Each vertical's capex is a share of its own revenue, which is the right shape for capacity that scales with sales. These are not that: fixed-size programmes with their own schedule that spend whether or not any segment grows. They are added on top, and they are why free cash flow dips in the years below.
Corporate capital expenditure
2026 Q3 → 2031 Q2The $101M of capital expenditure disclosed against the Corporate reconciling line in 2026 Q2, held flat across the horizon. It is carried here rather than inside a vertical because it belongs to none of them: as a percentage of the $37M of Corporate third-party revenue it would be 273%, an artefact of the denominator. This is not an invented programme - it is a disclosed quarterly outlay given a shape the engine can carry.
The projected path
| Quarter | Europe, Middle East & Africa | Latin America | North America | Asia Pacific | Bottling Investments | Corporate | Revenue | YoY | EBITDA | Capex | FCF | R40 | PV of FCF |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3E | $2.85B | $1.87B | $5.71B | $1.43B | $1.53B | $37M | $13.42B | +8% | $5.06B | $424M | $3.72B | +35 | $3.65B |
| 2026 Q4E | $2.53B | $1.90B | $5.19B | $1.16B | $527M | $38M | $11.34B | −4% | $4.55B | $343M | $3.37B | +26 | $3.24B |
| 2027 Q1E | $2.76B | $1.93B | $5.08B | $1.44B | $528M | $38M | $11.77B | −6% | $4.76B | $343M | $3.53B | +24 | $3.34B |
| 2027 Q2E | $3.23B | $1.96B | $5.74B | $1.55B | $529M | $38M | $13.05B | −2% | $5.24B | $372M | $3.90B | +27 | $3.61B |
| 2027 Q3E | $2.98B | $1.98B | $6.05B | $1.49B | $531M | $39M | $13.08B | −3% | $5.23B | $378M | $3.89B | +27 | $3.53B |
| 2027 Q4E | $2.64B | $2.01B | $5.50B | $1.21B | $532M | $39M | $11.93B | +5% | $4.79B | $355M | $3.56B | +35 | $3.17B |
| 2028 Q1E | $2.88B | $2.04B | $5.37B | $1.50B | $534M | $39M | $12.37B | +5% | $5.00B | $354M | $3.72B | +35 | $3.25B |
| 2028 Q2E | $3.37B | $2.07B | $6.07B | $1.62B | $535M | $40M | $13.70B | +5% | $5.51B | $385M | $4.11B | +35 | $3.52B |
| 2028 Q3E | $3.10B | $2.10B | $6.39B | $1.56B | $537M | $40M | $13.72B | +5% | $5.49B | $392M | $4.09B | +35 | $3.44B |
| 2028 Q4E | $2.75B | $2.12B | $5.80B | $1.26B | $538M | $40M | $12.51B | +5% | $5.03B | $367M | $3.74B | +35 | $3.08B |
| 2029 Q1E | $3.00B | $2.15B | $5.66B | $1.57B | $540M | $41M | $12.95B | +5% | $5.25B | $366M | $3.91B | +35 | $3.16B |
| 2029 Q2E | $3.50B | $2.18B | $6.39B | $1.70B | $541M | $41M | $14.34B | +5% | $5.77B | $398M | $4.31B | +35 | $3.42B |
| 2029 Q3E | $3.22B | $2.20B | $6.72B | $1.63B | $543M | $42M | $14.36B | +5% | $5.76B | $405M | $4.29B | +35 | $3.34B |
| 2029 Q4E | $2.85B | $2.23B | $6.10B | $1.32B | $545M | $42M | $13.09B | +5% | $5.27B | $379M | $3.92B | +35 | $2.99B |
| 2030 Q1E | $3.11B | $2.26B | $5.94B | $1.64B | $546M | $42M | $13.54B | +5% | $5.49B | $378M | $4.10B | +35 | $3.07B |
| 2030 Q2E | $3.63B | $2.29B | $6.71B | $1.77B | $548M | $43M | $14.99B | +5% | $6.04B | $411M | $4.51B | +35 | $3.32B |
| 2030 Q3E | $3.35B | $2.32B | $7.06B | $1.70B | $549M | $43M | $15.02B | +5% | $6.02B | $418M | $4.49B | +34 | $3.24B |
| 2030 Q4E | $2.96B | $2.35B | $6.40B | $1.38B | $551M | $43M | $13.68B | +5% | $5.52B | $391M | $4.11B | +35 | $2.91B |
| 2031 Q1E | $3.23B | $2.37B | $6.24B | $1.71B | $553M | $44M | $14.15B | +5% | $5.75B | $390M | $4.29B | +35 | $2.98B |
| 2031 Q2E | $3.77B | $2.40B | $7.05B | $1.85B | $554M | $44M | $15.66B | +4% | $6.32B | $425M | $4.72B | +35 | $3.21B |
Every row is projected. A year-over-year change is shown only where the quarter it compares against exists — an em dash means there is no comparable quarter, not a flat year.
Model revisions
Assumptions are marked to reality as each quarter prints. Every change is appended here, with the fair value the model produced at the time, so the model's own history stays visible.
| Date | Fair value then | Note |
|---|---|---|
| 2026-08-27 | $80.21 | First published model, built from the verified 2026 Q2 research brief. Six third-party revenue lines - the five reportable segments plus the Corporate reconciling line - which sum to reported consolidated revenue in all ten historical quarters with no elimination plug. Day-normalised seasonality on EMEA, North America and Asia Pacific; the other three verticals left aseasonal on the evidence. The African bottling deconsolidation is a dated level step on Bottling Investments rather than a growth rate. |